OCUL
insider transactionsOCULAR THERAPEUTIX, INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 365 days, totalling $492.4K.
Net shares · 365d
-179.8K
61.2K buy · 241.0K sell
Net value · 365d
-$1.6M
$492.4K in · $2.1M out
Sentiment · 365d
Net selling
19% buying · 81% selling
Open-market trades · 365d
18
61.2K buy · 241.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·G
Dugel Pravin KEY
Executive Chairman, President…
$0
50.1K sh
Own -2%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +16%
-
Grant·A
Chief Financial Officer
$0
14.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
15.4K sh
Own +29%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +30%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +27%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +6%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +30%
-
Grant·A
Director
$0
44.0K sh
Own New
-
Grant·A
Director
$0
14.0K sh
Own +28%
-
Sell·S
Chief Medical Officer · 10b5-1
$122.6K
14.8K sh · $8.27
Own -5%
-
Other·G
Dugel Pravin KEY
Executive Chairman, President… · 10b5-1
$0
394.7K sh
Own -100%
-
Sell·S
Chief Strategy Officer · 10b5-1
$15.2K
1.9K sh · $8.20
Own -1%
-
Sell·S
Chief Development Officer · 10b5-1
$24.3K
3.0K sh · $8.20
Own -1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$24.7K
3.0K sh · $8.20
Own -1%
-
Sell·S
Dugel Pravin KEY
Executive Chairman, President… · 10b5-1
$173.5K
21.2K sh · $8.20
Own -1%
-
Buy·P
Director
$31.1K
1.0K sh · $31.07
Own New
-
Grant·A
Director
$0
24.4K sh
Own +24%
-
Other·G
Dugel Pravin KEY
Executive Chairman, President…
$0
394.7K sh
Own -13%
-
Sell·S
Chief Strategy Officer · 10b5-1
$14.6K
1.8K sh · $8.28
Own -1%
-
Sell·S
Chief Development Officer · 10b5-1
$23.3K
2.8K sh · $8.28
Own -1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$25.3K
3.1K sh · $8.28
Own -1%
-
Sell·S
Dugel Pravin KEY
Executive Chairman, President… · 10b5-1
$166.1K
20.1K sh · $8.28
Own -1%
-
Sell·S
Chief Medical Officer · 10b5-1
$27.2K
3.5K sh · $7.74
Own -1%
-
Buy·P
Director
$461.4K
60.2K sh · $7.66
Own +32%
-
Sell·S
Chief Medical Officer · 10b5-1
$71.1K
7.9K sh · $9.04
Own -2%
-
Sell·S
Chief Operating Officer
$103.5K
11.4K sh · $9.04
Own -3%
-
Sell·S
Chief Strategy Officer · 10b5-1
$93.5K
10.3K sh · $9.04
Own -3%
-
Sell·S
Dugel Pravin KEY
Executive Chairman, President… · 10b5-1
$1.1M
124.9K sh · $9.04
Own -4%
-
Sell·S
Chief Operating Officer
$51.5K
6.0K sh · $8.54
Own -2%
-
Sell·S
Chief Operating Officer
$49.9K
5.5K sh · $9.14
Own -1%
-
Grant·A
Global CCO
$0
416.0K sh
Own New
-
Grant·A
Global CCO
$0
136.0K sh
Own New
-
Grant·A
Interim CFO
$0
33.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
240.9K sh
Own New
-
Grant·A
Chief Business Officer
$0
79.1K sh
Own +45%
-
Grant·A
Chief Medical Officer
$0
240.9K sh
Own New
-
Grant·A
Chief Medical Officer
$0
79.1K sh
Own +32%
-
Grant·A
Donald Notman KEY
Chief Financial Officer and C…
$0
240.9K sh
Own New
-
Grant·A
Donald Notman KEY
Chief Financial Officer and C…
$0
79.1K sh
Own +26%
-
Grant·A
Chief Strategy Officer
$0
197.7K sh
Own New
-
Grant·A
Chief Strategy Officer
$0
64.9K sh
Own +23%
-
Grant·A
Chief Commercial Officer
$0
197.7K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
64.9K sh
Own +42%
-
Grant·A
Chief Development Officer
$0
240.9K sh
Own New
-
Grant·A
Chief Development Officer
$0
79.1K sh
Own +41%
-
Grant·A
Chief Scientific Officer
$0
240.9K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
79.1K sh
Own +32%
-
Grant·A
Chief Legal Officer
$0
197.7K sh
Own New
-
Grant·A
Chief Legal Officer
$0
64.9K sh
Own +74%
-
Grant·A
Director
—
23.6K sh
Own +30%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Dugel Pravin KEY | Other G | 50.1K | $0 |
| Jun 10, 2026 | Charles M Warden | Grant A | 44.0K | $0 |
| Jun 10, 2026 | Charles M Warden | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Jason Shand Robins KEY | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Jason Shand Robins KEY | Grant A | 15.4K | $0 |
| Jun 10, 2026 | RAINES MERILEE | Grant A | 44.0K | $0 |
| Jun 10, 2026 | RAINES MERILEE | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Leslie J. Williams | Grant A | 44.0K | $0 |
| Jun 10, 2026 | Leslie J. Williams | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Richard L Lindstrom MD | Grant A | 44.0K | $0 |
| Jun 10, 2026 | Richard L Lindstrom MD | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Seung Suh Hong | Grant A | 44.0K | $0 |
| Jun 10, 2026 | Seung Suh Hong | Grant A | 14.0K | $0 |
| Jun 10, 2026 | Adrienne L Graves | Grant A | 44.0K | $0 |
| Jun 10, 2026 | Adrienne L Graves | Grant A | 14.0K | $0 |
| Jun 3, 2026 | Nadia Waheed 10b5-1 | Sell S | 14.8K | $122.6K |
| May 28, 2026 | Dugel Pravin KEY 10b5-1 | Other G | 394.7K | $0 |
| May 26, 2026 | Sanjay Nayak 10b5-1 | Sell S | 1.9K | $15.2K |
| May 26, 2026 | Peter Kaiser 10b5-1 | Sell S | 3.0K | $24.3K |
| May 26, 2026 | Jeffrey S. Heier 10b5-1 | Sell S | 3.0K | $24.7K |
| May 26, 2026 | Dugel Pravin KEY 10b5-1 | Sell S | 21.2K | $173.5K |
| May 18, 2026 | Adrienne L Graves | Buy P | 1.0K | $31.1K |
| Apr 20, 2026 | Adrienne L Graves | Grant A | 24.4K | $0 |
| Apr 9, 2026 | Dugel Pravin KEY | Other G | 394.7K | $0 |
| Feb 23, 2026 | Sanjay Nayak 10b5-1 | Sell S | 1.8K | $14.6K |
| Feb 23, 2026 | Peter Kaiser 10b5-1 | Sell S | 2.8K | $23.3K |
| Feb 23, 2026 | Jeffrey S. Heier 10b5-1 | Sell S | 3.1K | $25.3K |
| Feb 23, 2026 | Dugel Pravin KEY 10b5-1 | Sell S | 20.1K | $166.1K |
| Feb 20, 2026 | Nadia Waheed 10b5-1 | Sell S | 3.5K | $27.2K |
| Feb 20, 2026 | Richard L Lindstrom MD | Buy P | 60.2K | $461.4K |
| Feb 12, 2026 | Nadia Waheed 10b5-1 | Sell S | 7.9K | $71.1K |
| Feb 12, 2026 | Donald Notman | Sell S | 11.4K | $103.5K |
| Feb 12, 2026 | Sanjay Nayak 10b5-1 | Sell S | 10.3K | $93.5K |
| Feb 12, 2026 | Dugel Pravin KEY 10b5-1 | Sell S | 124.9K | $1.1M |
| Feb 4, 2026 | Donald Notman | Sell S | 6.0K | $51.5K |
| Feb 2, 2026 | Donald Notman | Sell S | 5.5K | $49.9K |
| Jan 21, 2026 | David Wayne Robinson | Grant A | 416.0K | $0 |
| Jan 21, 2026 | David Wayne Robinson | Grant A | 136.0K | $0 |
| Jan 20, 2026 | Jason Shand Robins KEY | Grant A | 33.0K | $0 |
| Jan 2, 2026 | Namrata Saroj | Grant A | 240.9K | $0 |
| Jan 2, 2026 | Namrata Saroj | Grant A | 79.1K | $0 |
| Jan 2, 2026 | Nadia Waheed | Grant A | 240.9K | $0 |
| Jan 2, 2026 | Nadia Waheed | Grant A | 79.1K | $0 |
| Jan 2, 2026 | Donald Notman KEY | Grant A | 240.9K | $0 |
| Jan 2, 2026 | Donald Notman KEY | Grant A | 79.1K | $0 |
| Jan 2, 2026 | Sanjay Nayak | Grant A | 197.7K | $0 |
| Jan 2, 2026 | Sanjay Nayak | Grant A | 64.9K | $0 |
| Jan 2, 2026 | Steve Lawrence Meyers | Grant A | 197.7K | $0 |
| Jan 2, 2026 | Steve Lawrence Meyers | Grant A | 64.9K | $0 |
| Jan 2, 2026 | Peter Kaiser | Grant A | 240.9K | $0 |
| Jan 2, 2026 | Peter Kaiser | Grant A | 79.1K | $0 |
| Jan 2, 2026 | Jeffrey S. Heier | Grant A | 240.9K | $0 |
| Jan 2, 2026 | Jeffrey S. Heier | Grant A | 79.1K | $0 |
| Jan 2, 2026 | Todd Anderman | Grant A | 197.7K | $0 |
| Jan 2, 2026 | Todd Anderman | Grant A | 64.9K | $0 |
| Jan 1, 2026 | Adrienne L Graves | Grant A | 23.6K | — |
About OCUL insider trading
This page tracks insider transactions for OCULAR THERAPEUTIX, INC (OCUL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.